Reimbursement policy for new medical technologies must balance creating incentives for innovation and keeping costs affordable. Currently developers of novel and complex genetic and molecular tests are primarily reimbursed according to fee schedules How well do current reimbursement methods reflect the value of new diagnostics in patient care and provide incentives for development of products? How might new approaches to reimbursement or incorporate the value of diagnostics in providing information to providers and patients, generate patient outcomes or reducing the need for inappropriate care? This panel will consider coding issues, economics, and value remembering that no stakeholder wants to drive up healthcare costs, how do we pay? Moderator: Steve Gutman, BCBS Technology Evaluation Center Rina Wolf, XIFIN Patrick Terry, Scientia Advisors Brian Carey, Foley Hoag LLP Elaine Jeter, Palmetto GBA
0 comments: